Literature DB >> 21246581

The in vitro PDT efficacy of a novel metallophthalocyanine (MPc) derivative and established 5-ALA photosensitizing dyes against human metastatic melanoma cells.

C A Robertson1, H Abrahamse, Denise Evans.   

Abstract

BACKGROUND AND
OBJECTIVE: Numerous worldwide clinical trials have shown that photodynamic therapy (PDT) represents an effective and safe modality for various skin disorders, but little research has been done in terms of its effect on malignant melanomas (MM). Thus, the aim of this study was to compare the effect of both established porphyrin photosensitizer 5-aminolevulinic acid (5-ALA) and novel metallophthalocyanine (MPc) photosensitizer on human metastatic skin cells which produce a MM.
MATERIALS AND METHODS: The cellular responses following PDT were assessed using changes in cell morphology, cell viability, cytotoxicity, apoptosis, and proliferation.
RESULTS: Findings reported that in vitro human MM cell line A375 (EACC no: 88113005) are highly sensitive to growth inhibition and apoptosis induction by the cytotoxic side-effects induced by MPc and 5-ALA photosensitizing treatments post-laser irradiation at 680 and 636 nm, respectively. The decrease of cell viability accompanied by an increased cytotoxicity and apoptotic and necrotic levels, with a time-dependant decrease in cellular proliferation was found to be far more significant for MPc-treated cells than 5-ALA-treated cells, since MPc was applied in far lower concentrations and exhibited far less photoxicity to control cells.
CONCLUSION: Hence, novel MPc proved to be the better photosensitizing dye for metastatic melanoma tumor destruction in combination with laser irradiation and is a particularly attractive photosensitizer since it exhibits so many ideal properties of a photosensitizing agent, thus further research of this possible anticancer agent could contribute to its potential application in PDT cancer treatment of MMs.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21246581     DOI: 10.1002/lsm.20980

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  7 in total

1.  High Aspect Ratio Nanotubes Formed by Tobacco Mosaic Virus for Delivery of Photodynamic Agents Targeting Melanoma.

Authors:  Karin L Lee; Bradley L Carpenter; Amy M Wen; Reza A Ghiladi; Nicole F Steinmetz
Journal:  ACS Biomater Sci Eng       Date:  2016-03-23

Review 2.  Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment.

Authors:  Renzo Emanuel Vera; María Julia Lamberti; Viviana Alicia Rivarola; Natalia Belén Rumie Vittar
Journal:  Tumour Biol       Date:  2015-09-29

Review 3.  Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

4.  Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells.

Authors:  Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Oncotarget       Date:  2019-10-22

Review 5.  Nanoparticle-Based Drug Delivery Systems for Photodynamic Therapy of Metastatic Melanoma: A Review.

Authors:  Nkune Williams Nkune; Heidi Abrahamse
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

6.  Photodynamic therapy of melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers - a comparative study.

Authors:  Ioana Baldea; Rodica-Mariana Ion; Diana Elena Olteanu; Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip
Journal:  Clujul Med       Date:  2015-04-15

Review 7.  Systematic Review and Meta-Analysis of In Vitro Anti-Human Cancer Experiments Investigating the Use of 5-Aminolevulinic Acid (5-ALA) for Photodynamic Therapy.

Authors:  Yo Shinoda; Daitetsu Kato; Ryosuke Ando; Hikaru Endo; Tsutomu Takahashi; Yayoi Tsuneoka; Yasuyuki Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.